Headache Disorders  >>  telcagepant (MK-0974)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
telcagepant (MK-0974) / Merck (MSD)
NCT00797667: MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

Terminated
2a
660
NA
Telcagepant 140 mg, MK-0974, Telcagepant 280 mg, 140 mg telcagepant placebo, 280 mg telcagepant placebo
Merck Sharp & Dohme LLC
Migraine
05/09
05/09
NCT00758836 / 2008-004095-43: A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)

Completed
2a
683
NA
placebo, ibuprofen, acetominophen, N-acetyl-p-aminophenol (APAP), telcagepant, MK-0974
Merck Sharp & Dohme LLC
Migraine
08/09
08/09
NCT00246337: A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Completed
2
420
US
Comparator: Placebo, MK0974, Rizatriptan
Merck Sharp & Dohme LLC
Migraine
05/06
05/06

Download Options